Microbial Fermentation Technology Market Size & Share, by Application (Antibiotics, Probiotics Supplements, Monoclonal Antibodies, Recombinant Proteins, Biosimilars, Vaccines, Enzymes, Small Molecules); End-User (Bio-Pharmaceutical Companies, Contract Research Organizations (CROs), CMOs & CDMOs, Academic & Research Institutes); Type (Medical, Industrial, Alcohol Beverages, Food and Feed Products) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5329
  • Published Date: Oct 18, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Microbial Fermentation Technology Market size is poised to reach USD 63 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of microbial fermentation technology was USD 33 Billion. The reason behind the growth is due to the rising need for vaccines. Microbial fermentation is a potent, adaptable microbiology method used to generate microbial cells or biomass such as proteins and enzymes for vaccine synthesis, and is also considered crucial in the production of mRNA vaccines. Moreover, it is the most prevalent process of vaccine manufacture followed by purification, which takes about 3 weeks. According to the World Health Organization (WHO), in 2021, over 16 billion vaccination shots costing USD 141 billion were distributed across the globe.

The growing need for microbial contract manufacturing services is believed to fuel the market growth. It has led to the development of a wide range of microbial products, microbial biomass, and enzymes, and has enabled many sorts of bulk manufacturing based on microbial fermentation.  Besides this, it has led to advancements in bioprocessing which would make the fermentation process more efficient and reliable in the coming years.

Microbial Fermentation Technology Market Overview
Get more information on this report: Request Free Sample PDF

Microbial Fermentation Technology Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Need for Fermented Food – Fermentation of food is done by regulating microbial development, which involves microorganisms such as yeast and bacteria enzymatically breaking down carbohydrates to produce carbon dioxide, organic acids, or alcohol, and the process also contributes to food sustainability by preserving, securing, and producing food components.
  • Increasing Popularity of CRISPR-Cas9 Technology- CRISPR-Cas9 technology transforms bacteria to boost target product yield and is capable of expanding the range of compounds and products available through fermentation.
  • Growing Adoption of Artificial Intelligence and Machine Learning- AI technology is extremely significant in the development of precision fermentation which is based on the use of microbes – mainly yeasts and fungi and may also assist in developing unique food products that meet the growing customer demand for natural, functional, and sustainable food options.

Additionally, Artificial intelligence is now being utilized to control fermentation operations in real time, and it can analyze past data to forecast future outcomes.

  • Spiking Cases of Infectious Diseases- This may lead to higher production of vaccines and antiviral drugs which are produced using microbial fermentation technology.
  • Rising Need for Gasoline- This has led to an increase in the production of biofuels such as ethanol and butanol which are produced by microbial fermentation that converts sugars derived from lignocellulosic biomass.
  • Growing Production of Biosimilars- Biosimilars are produced using are produced by living cells such as bacteria or yeast and are often produced by advanced fermentation technology.
  • Higher Usage of Single-Use Bioreactor Systems- Single-use bioreactor Systems (SUB Disposable) can be used for microbial fermentation as they reduce the risk of cross-contamination which helps in meeting the stringent regulations of the pharmaceutical industry.


  • High Cost of Microbial Fermentation Technology – The research & development for developing a new fermentation process involves a huge cost as it requires skilled labor, high-quality raw materials, and energy-intensive equipment. This may make it difficult for pharmaceutical companies with limited budgets to carry out these processes. Furthermore, setting up a fermentation plant, which includes the cost of labor and other costs incurred to maintain the facility, can easily cost tens to hundreds of millions of dollars.
  • Stringent Regularity Requirements for Biopharmaceutical Production
  • Risk of Microbial Contamination Leading to Product Loss

Microbial Fermentation Technology Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 33 Billion

Forecast Year Market Size (2036)

~ USD 63 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Microbial Fermentation Technology Segmentation

Application (Antibiotics, Probiotics Supplements, Monoclonal Antibodies, Recombinant Proteins, Biosimilars, Vaccines, Enzymes, Small Molecules)

The antibiotics segment in the microbial fermentation technology market is estimated to gain a robust revenue share of 33% in the coming years owing to the rising consumption of antibiotics as they have had enormous success in improving health outcomes Moreover, it is expected that increasing personal incomes, and health insurance have driven the consumption of antibiotics across the globe. Antibiotics, the most significant category of bioactive chemicals, can be produced using microbiology through the fermentation method, in which the source microbe is cultured in big containers holding a liquid growth medium. 

For instance, Penicillin is an antibiotic used to treat infections in the mouth, throat, gums, and respiratory tract, and urine is created by the fermentation process. It is manufactured in a fermenter that is incubated at around 25oC to 26oC for approximately 5 to 7 days at pH 7 to 7.4 and can be mass-produced through the use of deep-tank batch fermentation. The demand for biopharma products is expanding in several nations owing to rising health concerns and advancements in biotechnology are expected to create profitable possibilities during the forecast period. According to estimates, antibiotic usage is expected to rise by more than 150% globally between 2015 and 2030.

Besides this, the recombinant proteins are poised to gain a notable share by the year 2036. Recombinant proteins are proteins that are encoded by recombinant DNA that facilitates gene expression and messenger RNA translation and are proteins that are generated artificially by inserting certain genes into host organisms such as bacteria or yeast.

End-User (Bio-Pharmaceutical Companies, Contract Research Organizations (CROs), CMOs & CDMOs, Academic & Research Institutes)

The biopharmaceutical companies segment in the microbial fermentation technology market is set to garner a notable share shortly on account of the rising need for biopharmaceutical products. Biopharma products such as enzymes, vaccines, antibiotics, and monoclonal antibiotics are in high demand which is expected to create a huge demand for microbial fermentation technology during the projection period. Moreover, biopharmaceuticals are mostly recombinant therapeutic proteins the production of which, employs a variety of procedures including fermentation that are thought to be crucial in their production. Additionally, many biopharmaceutical and biological products rely on (various) cell-type fermentation where microorganisms such as bacteria, yeast, and molds are increasingly being employed to produce biopharmaceuticals such as vaccines, recombinant proteins, antibiotics, and active pharmaceutical ingredients (APIs).

Furthermore, the CMOs & CDMOs are expected to hold a significant share during the forecast timeframe. CMOs and CDMOs are quickly becoming the preferred choice for biotherapeutics as they can produce industrial enzymes through fermentation. For instance, it is estimated that over 25% of biologics are manufactured by CDMOs/CMOs.

Our in-depth analysis of the global microbial fermentation technology market includes the following segments:


  • Antibiotics
  •  Probiotics Supplements
  • Monoclonal Antibodies
  • Recombinant Proteins
  •  Biosimilars
  •  Vaccines
  • Enzymes
  • Small Molecules


  • Bio-Pharmaceutical Companies
  • Contract Research Organizations (CROs)
  •  CMOs & CDMOs
  • Academic & Research Institutes


  • Medical
  •  Industrial
  •  Alcohol Beverages
  • Food and Feed Products

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Microbial Fermentation Technology Industry - Regional Synopsis

APAC Market Forecast

Microbial fermentation technology market in Asia Pacific is predicted to account for the largest share of 42% by 2036 impelled by the presence of the developed chemical sector.  China's chemical industry continues to outperform all others as the country’s chemical sector has been the world's largest in terms of sales. This has led to the development of the fermentation industry in the country. For instance, China has the world's largest fermentation industry, accounting for more than 60% of the global market share for amino acids, vitamins, and other fermentation products. As a result, the role of fermentation has been increased in various industries which has directly boosted the demand for microbial fermentation technology in the region. China's share of global chemical market sales in 2021 increased to more than 42%, up from around 27% in 2011.

North American Market Statistics

The North America microbial fermentation technology market is estimated to be the second largest, during the forecast timeframe led by an increase in contract development organizations. Moreover, these organizations provide a variety of services to pharmaceutical and biotech companies, boosting development and manufacturing productivity while reducing downtime and expenses. Additionally, contract development and manufacturing organizations (CDMOs) provide a variety of pharmaceutical CDMO services and offer process development and cGMP production in cell culture, microbial fermentation, and gene treatments.

Research Nester
Microbial Fermentation Technology Market Region
Get more information on this report: Request Free Sample PDF

Companies Dominating the Microbial Fermentation Technology Landscape

    • Biocon Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • BioVectra Inc.
    • Danone UK
    • F. Hoffmann-La Roche AG
    • Koninklijke DSM NV
    • Lonza
    • Novozymes A/S
    • TerraVia Holdings, Inc.
    • Royal DSM

In the News

  • BioVectra Inc. announced to diversification of manufacturing Capacity with Single-Use Microbial Fermentation Technology to support even more potential biologics for technology transfer and optimization, and offer enhanced flexibility, faster turnaround times, and increased capacity utilization to the customers. Furthermore, single-use sterile fermenters are intended to offer mixing, oxygen transmission, and cooling and provide a unique option and a significant benefit over stainless-steel fermenters in terms of batch segregation and cross-contamination hazards.
  • Danone UK partnered with Chr Hansen to push for innovation in both dairy and plant-based products and supply its 1800 strains of ferments to further research on the gut microbiome to focus on customer health and improve sustainability by reducing greenhouse gas emissions in its supply chain

Author Credits:  Radhika Pawar

  • Report ID: 5329
  • Published Date: Oct 18, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rising need for vaccines and the growing need for microbial contract manufacturing services are the major factors driving the growth of the market.

The market size of Microbial Fermentation Technology is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.

The major players in the market are BioVectra Inc., Danone UK, F. Hoffmann-La Roche AG, Koninklijke DSM NV, Lonza, Novozymes A/S, TerraVia Holdings, Inc., BIOZEEN

The antibiotics segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Microbial Fermentation Technology Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying